Skip to main content

Advertisement

Table 2 Comparison of ≥ Grade 3 toxicities rates between irinotecan-containing doublet versus irinotecan monotherapy

From: Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer

Adverse events Irinotecan-containing doublet event/total (%) Irinotecan monotherapy event/total (%)
Neutropenia 142/425 (33.4) 128/483 (26.5)
Anemia 68/425 (16.0) 36/483 (7.45)
Thrombocytopenia 9/395 (2.3) 9/454 (2.0)
Diarrhea 17/425 (4.0) 22/483 (4.6)
Nausea 21/373 (5.6) 25/430 (5.8)
Vomiting 6/267 (2.2) 8/272 (2.9)
Anorexia 47/425 (11.0) 50/483 (10.4)
Fatigue 16/395 (4.1) 17/454 (3.7)